-
Efficacy of Midostaurin in combination with intensive chemotherapy in young and elderly patients with AML with FLT3-ITD mutations
Time of Update: 2023-01-06
In a randomized Phase 3 pivotal CALGB 10603 (RATIFY) trial comparing placebo, patients aged 18 to 59 years with newly diagnosed AML with FLT3 mutation experienced significant improvements in overall survival (OS) and event-free survival (EFS) after receiving midostaurin plus intensive chemotherapy sequential 1-year midostaurin maintenance therapy.
-
Efficacy of Midostaurin in combination with intensive chemotherapy in young and elderly patients with AML with FLT3-ITD mutations
Time of Update: 2023-01-06
In a randomized Phase 3 pivotal CALGB 10603 (RATIFY) trial comparing placebo, patients aged 18 to 59 years with newly diagnosed AML with FLT3 mutation experienced significant improvements in overall survival (OS) and event-free survival (EFS) after receiving midostaurin plus intensive chemotherapy sequential 1-year midostaurin maintenance therapy.
-
More contagious and escapeous! The Omicron variant has mutated again!
Time of Update: 2023-01-05
7 variant are mainly manifested as high fever, persistent cough, body aches, headache, sore throat, olfactory changes and loss of appetite, which are similar to those after infection with the early Omicron subtype variant of the new crown.
-
Precise genome editing of RBM20 pathogenic mutations may salvage dilated cardiomyopathy
Time of Update: 2023-01-05
The findings suggest that precise correction of gene mutations using precise gene editing methods (single-gene diseases) may be a promising approach for treating dilated cardiomyopathy.
The findings suggest that precise correction of gene mutations using precise gene editing methods (single-gene diseases) may be a promising approach for treating dilated cardiomyopathy.
-
ESMO 2022 Professor Dongliang Yu: Incidence of EGFR mutation and disease prognosis in patients with locally resectable NSCLC in the real world
Time of Update: 2023-01-05
2Study designThe main inclusion criteria for the EXERPOS-GFPC study were: patients with local NSCLC who underwent continuous surgery in France from January 2018 to December 2019, and the study collected data including demographic and clinical data, type of surgery, stage, disease recurrence, and treatment in case of disease recurrence.
-
mutations and methylation changes in bile to diagnose pancreatobiliary cancer!
Time of Update: 2023-01-05
Patients with pancreatobiliary tract cancer generally have a poor clinical prognosis, with a 5-year overall survival rate of less than 20%. This is mainly related to late diagnosis. Accurate preoperat
-
The genetic mutation that causes autism has been found to overstimulate brain cells
Time of Update: 2023-01-05
Scientists trying to understand the underlying brain mechanisms of autism spectrum disorder have discovered that a genetic mutation known to be associated with the disorder causes overstimulation of brain cells to a much greater extent than neuronal cells that are not mutated.
-
, mechanism and treatment plan of rare EGFR19delins mutations
Time of Update: 2023-01-04
Patients with EGFR TKI-resistant advanced NSCLC may benefit from immunotherapy With the in-depth understanding of the immunomodulatory role of targeted drugs and the continuous generation of clinical evidence, immunotherapy is expected to bring new hope for driver-positive non-small cell lung cancer28.
-
: a systematic assessment of the sensitivity of 74,389 rare EGFR mutations to 5 first-line targeted inhibitors
Time of Update: 2023-01-04
Enrichment of EGFR Sub-Del library mutants and EGFR Ins-1 library variants for the cytotoxicity of five TKIsIn summary, the sensitivity of relevant mutations to five first-line EGFR-TKI-targeted drugs was evaluated by systematic drug sensitivity screening experiments for 7,4389 rare variants of EGFR gene in lung cancer.
-
HER2 exon 20 inserted mutation lung cancer (NSCLC) innovative drug! Pan-HER tyrosine kinase
Time of Update: 2023-01-01
The NDA seeks approval for poziotinib: a novel, oral, irreversible EGFR family receptor-blocking pan-HER inhibitor for the treatment of previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying HER2 exon 20 insertion mutations (Ex20ins).
-
Professor Xie Yuntao's team published a contralateral breast cancer risk prediction model for BRCA mutation patients in JCO
Time of Update: 2022-12-30
On December 8, 2022, the team of Professor Xie Yuntao of Peking University Cancer Hospital was published in the internationally renowned Journal of Clinical Oncology Published online titled "BRCA-CRisk: A contralateral breast cancer risk prediction model for BRCA carriers.
-
How are domestic and foreign guidelines recommended for adjuvant treatment of EGFR mutation NSCLC?
Time of Update: 2022-12-30
▌CSCO NSCLC diagnosis and treatment guidelines According to the Chinese Society of Clinical Oncology (CSCO) NSCLC diagnosis and treatment guidelines (2022 edition), the treatment of NSCLC still adopts comprehensive treatment based on pathological type, stage (according to the 8th edition of lung cancer staging criteria) and molecular classification [2]。 Regarding the adjuvant therapy of EGFR mutation-positive NSCLC, guidelines state that for patients with stage IIA, IIB, IIIA, or III.
-
Gene therapy can correct mutations in common heart diseases
Time of Update: 2022-12-30
Using the CRISPR-Cas9 gene-editing system, researchers at the University of Texas Southwestern corrected mutations in human cells and in mouse models of the disease that lead to a common inherited heart condition called dilated cardiomyopathy (DCM).
-
What? Automated microscopy can also do multiplex ddPCR to screen for cancer-related point mutations
Time of Update: 2022-12-29
Figure 7 Microdroplet multicolor fluorescence overlay shooting and nucleic acid concentration analysis Table 2 Statistics for calculating DNA concentrations at different targets By using 4-plex ddPCR combined with the Lionheart automated microscopic imaging platform, the excellent experimental data also demonstrate the high sensitivity of this technology, and also demonstrate the potential of its application in cancer screening.
-
The University of Pennsylvania has discovered why the cancer recurs due to BRCA mutations
Time of Update: 2022-12-04
In a new study published this week in Nature Communications, researchers compared a group of tumors from patients with primary and recurrent BRCA1/2 mutation-associated breast and ovarian cancers and found multiple features associated with recurrence, including those that promise to improve the ability of tumor repair treatments to cause DNA damage.